Earnings

aTyr Pharma Narrows Third-Quarter 2026 Net Loss to $18.3 Million

The Tip Desk · November 11, 2026 · 3 min read

Third-quarter 2026 revenue was zero, while net loss narrowed to $18.3 million. Cash, cash equivalents, restricted cash and investments were $50.3 million at September 30, 2026, as the company said the position funds current operations into late 2028.

aTyr Pharma, Inc. (ATYR), a clinical-stage biotechnology company developing medicines from its tRNA synthetase platform, reported zero revenue for the third quarter of 2026, versus $190,000 a year earlier. Net loss attributable to aTyr narrowed to $18.3 million, or $7.43 a share, from $25.7 million, or $10.60 a share. The company reached alignment with the U.S. Food and Drug Administration on the protocol for a global Phase 3 study of efzofitimod in patients with chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease, using forced vital capacity as the primary endpoint.

The company said it recently initiated study-related activities for the trial and is prioritizing strategic partnerships and/or licensing arrangements to advance the Phase 3 study beyond those initial activities. President and Chief Executive Officer Sanjay S. Shukla said the company believes the efzofitimod program is well-positioned given late-stage development status in an indication with a multi-billion-dollar global market opportunity, and that the best way to advance the asset at this time is through partnerships.

In the second quarter, aTyr had submitted the protocol in June 2026 and said it expected FDA comments by the end of August. That feedback cycle closed with the alignment described in the third-quarter update.

Enrollment was completed in the Phase 2 EFZO-CONNECT study of efzofitimod in limited or diffuse systemic sclerosis-related interstitial lung disease. Full study results are now expected in the second quarter of 2027, after the company had said topline results were expected in the first quarter of 2027. The company said the results will include data on the modified Rodnan Skin Score, skin histopathology, gene expression profiling, immune biomarkers, forced vital capacity, and an exposure-response analysis.

The company also published Phase 3 EFZO-FIT results of efzofitimod in pulmonary sarcoidosis in The Lancet Respiratory Medicine, and a manuscript on the mechanism of action and anti-fibrotic effects of ATYR0101 in the Journal of Biological Chemistry. It announced a research collaboration with Montefiore Einstein for preclinical studies of ATYR2810, a monoclonal antibody targeting the neuropilin-2 receptor, in pediatric osteosarcoma.

Research and development expenses were $10.4 million in the third quarter 2026, down from $22.1 million in the year-ago quarter. The company said those costs consisted primarily of the Phase 2 EFZO-CONNECT study and preclinical product candidates. General and administrative expenses were $8.3 million. License and collaboration agreement revenues were zero, versus $190 thousand a year earlier.

Net loss attributable to aTyr Pharma was $18.3 million, or $7.43 a share, in the third quarter 2026, versus $25.7 million, or $10.60 a share, a year earlier.

Cash, cash equivalents, restricted cash and available-for-sale investments were $50.3 million at September 30, 2026, down from $58.9 million at the end of the second quarter. Based on its current cash and operating-expense forecast, the company said the position will be sufficient to fund current operations into late 2028.

In the second quarter, aTyr had announced a workforce reduction of approximately 60% and program prioritization to conserve capital while awaiting FDA comments on the Phase 3 protocol. It said the restructuring and additional cost-saving measures were expected to reduce annualized operating expenses by approximately $13 million beginning in the fourth quarter of 2026. In its second-quarter announcement, the company said Jill Broadfoot was scheduled to step down as chief financial officer as of September 30, 2026, with Brandon Yaras scheduled to be appointed as CFO as of October 1, 2026. Nancy Denyes was scheduled to step down as general counsel as of September 30, 2026.

Efzofitimod is a tRNA synthetase-derived biologic immunomodulator in development for interstitial lung disease. The company said the proposed Phase 3 study is intended to enroll up to approximately 372 patients receiving oral corticosteroid at a stable dose of ≤5.0 mg daily and/or receiving a background immunosuppressant, with the primary endpoint as change from baseline in FVC at week 48.

More on ATYR

September 28, 2026 QBook Stronger demand supports expansion as pricing diverges

aTYR PHARMA INC — all coverage and financials